JPRN-UMIN000006514已完成未知
Phase II trial of irinotecan, paclitaxel plus bevacizumab for previously untreated patients with non-squamous and non-small cell lung cancer, detected the over-expression of ERCC1 by EBUS-GS. - Phase II trial of irinotecan, paclitaxel plus bevacizumab for patients with NSCLC
agasaki Thoracic Oncology Group0 个研究点目标入组 12 人开始时间: 2011年10月12日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
The triplet combination might be effective for patients with advanced, untreated NSCLC overexpressing ERCC1. ERCC1 messenger RNA levels may be a predictive factor for response to platinum-containing regimens.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)brain metastasis 2)cavity lesion 3)invasion of giant vessels 4)hemoptysis 5)history of radiotherapy for lung 6)interstitial pneumonitis 7)watery diarrhea 8)severe gastrointestinal disease 9)uncontrollable fever up 10)other sever disease 11)uncontrollable pericardial,pleural effusion and ascites 12)other carcinoma 13)sever allergy history 14)receiving anti-coagulate treatment without biaspilin 15)psychological disease 16)women with pregnant or under lactation 17)others diagnosed as inadequate case to enter the trial
研究者
相似试验
已完成
2 期
Phase II study of irinotecan and amrubicin for relapsed non-small-cell lung cancerJPRN-C000000131Okayama Lung Cancer Study Group30
终止
1 期
Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLCNon-Small Cell Lung CancerNCT02382406Nisha Mohindra, MD46
已完成
2 期
Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung CancerExtensive Stage Small Cell Lung CancerNCT00118235National Cancer Institute (NCI)72
已完成
2 期
CBDCA, PTX and BV for NSCLC (non-sq) with IPon-squamous, non-small cell lung cancerLung cancerJPRN-jRCTs061180046Katakami Nobuyuki21
已完成
2 期
Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung CancerNon-Small Cell Lung CancerNCT00741988SCRI Development Innovations, LLC82